Synonyms: MG531 | Nplate®
romiplostim is an approved drug (FDA (2008), EMA (2009))
Compound class:
Peptide
Comment: This drug is a thrombopoietin receptor agonist, although its peptide sequence does not resemble that of the endogenous peptide thrombopoietin. Romiplostim is known as a peptibody, a fusion between the Fc portion of immunoglobulin and a therapeutic peptide. In this case the drug exists as a heterodimer. The carboxy terminal 14 amino acid residues of this peptibody constitute the thrombopoietin receptor binding domain (single letter amino acid code: IEGPTLRQWLAARA).
|
Immunopharmacology Comments |
Increases the platelet count in ITP patients via activation of the thrombopoietin receptor to combat the autoimmune destruction of platelets in this disease. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Autoimmune thrombocytopenic purpura |
Disease Ontology:
DOID:8924 OMIM: 188030 Orphanet: ORPHA3002 |
Approved drug for autoimmune thrombocytopenic purpura (a.k.a. idiopathic thrombocytopenic purpura) |